オプションチェーンは、Remitly Globalの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Remitly Globalの市場センチメントを評価します。.

Remitly Global (NASDAQ:RELY) 株価情報, オプションチェーン

Remitly Global

Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. The company's revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.

Remitly Global Inc

Macro Economic Events

News

Global

Economics

A Group Of Canada Premiers Expected To Meet With President Trump At White House On Wednesday

Official inflation numbers came out yesterday morning, showing an increase across the board. This has stoked fears the Fed may not decrease rates and may have to even increase rates in an already fragile environment.
Pretty much every ticker across the board dipped on the news, while some bounced back a little later. NVDA dropped from $134 to $129 on the news and has since bounced back above $130. But it's barely holding on. The question on traders' minds is "is it time to dip buy NVDA?"
Let's dive into how my PFP system is looking at NVDA and how we're looking to trade it.
<h2 class="wp-block-heading">Options Positioning in NVDA</h2>
Looking at the positional chart below (notional gamma) for NVDA, we can see $130 is a massive level. There are definitely more calls than puts at $130 (blue line) but the largest amount of put gamma (for the February options expiration) is at $130.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="602" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12131902/echarts-1-1024x602.png" alt="" class="wp-image-779371" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12131902/echarts-1-1024x602.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12131902/echarts-1-300x176.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12131902/echarts-1-768x451.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12131902/echarts-1.png 1310w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
This makes the $130 level the TGS (top gamma strike) and bulls will want to hold this to retain a bullish bias and a modicum of control.
If NVDA can hold and ideally regain some ground, then this favors staying bullish on NVDA, so if you don't have a bullish position, and feel $130 will hold, this is your line in the sand to get long.
On the other side, if we start to close below $130, puts will be mostly in control. This lends itself to more volatility and bears having a greater influence on the price action. Thus, if you want to establish a bearish position, you'd want to see a daily close under $130 to get bearish. We see almost the same fuel at $125 and $120, so those would be our downside targets if we got bearish.
<h2 class="wp-block-heading">Option Flows for NVDA</h2>
As I'm writing this on Wednesday morning, the NVDA option flows are neutral to mildly bearish with traders selling a mild amount of calls (-17M notional deltas) and buying a small amount of puts (-9M notional deltas). This is a very modicum of bearish flows.
Traders simply aren't hitting the gas to buy hand over fist, but they're not establishing seriously bearish positions (yet).
I think a daily close under $130 likely ignites more bearish positions, but this is not the flow I want to see to buy the dip.
<h2 class="wp-block-heading">Price Action in NVDA</h2>
Looking at the chart below, we can see the impulsive selling pre-market from the core inflation print, and a corrective bounce since. This corrective bounce is not the most inspiring, and clearly matches the lackluster buying response in the option flows.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="502" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12131857/NVDA_2025-02-12_10-05-36-1024x502.png" alt="" class="wp-image-779370" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12131857/NVDA_2025-02-12_10-05-36-1024x502.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12131857/NVDA_2025-02-12_10-05-36-300x147.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12131857/NVDA_2025-02-12_10-05-36-768x377.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12131857/NVDA_2025-02-12_10-05-36-1536x753.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12131857/NVDA_2025-02-12_10-05-36.png 1835w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
5-minute NVDA chart
$130 is the TGS, so it's not surprising to see a fair dinkum of price action around there. Regaining $133.5 helps as it would have recovered the CPI losses while losing $130 on a daily closing basis could add fresh technical selling.
<h2 class="wp-block-heading">How We're Trading NVDA</h2>
I'm watching this corrective bounce very carefully for subtle clues which way it wants to break, but it's a fragile position for bulls while inside this corrective structure. Flows haven't shown a major bias yet, so I think the best thing is to stay put and look for conviction in the option flows and a break of the corrective structure.
I'll share our live trade ideas in real time with our members of the <a href="https://www.benzinga.com/premium/ideas/benzinga-options-school-webinar">Benzinga Option School</a> or <a href="https://www.benzinga.com/premium/ideas/trading-waves-997-offer/">Trading Waves</a>, so make sure to join and see how I'm trading it. I hope to see you there soon.

Opinion

Trading Ideas

Should You Buy This Nvidia Dip?

President Trump Says Spoke With Ukraine's Zelenskiy About Meeting On Friday In Munich To Be Led By Vice President Vance And Secretary Of State Rubio

Barrington Research analyst Gary Prestopino maintains Cantaloupe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTLP#NASDAQ">CTLP</a>) with a Outperform and raises the price target from $12 to $14.

Price Target

Analyst Ratings

CTLP

Barrington Research Maintains Outperform on Cantaloupe, Raises Price Target to $14

Ameriprise Finl's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMP#NYSE">AMP</a>) short percent of float has fallen 5.19% since its last report. The company recently reported that it has 1.06 million shares sold short, which is 1.28% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.73 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Ameriprise Finl Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739384121_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Ameriprise Finl has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Ameriprise Finl's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Ameriprise Finl's peer group average for short interest as a percentage of float is 3.27%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

(AMP) - Analyzing Ameriprise Finl's Short Interest

WR Berkley's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WRB#NYSE">WRB</a>) short percent of float has risen 40.99% since its last report. The company recently reported that it has 6.76 million shares sold short, which is 2.27% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.44 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>WR Berkley Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739384115_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for WR Berkley has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing WR Berkley's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, WR Berkley's peer group average for short interest as a percentage of float is 2.10%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into WR Berkley's Recent Short Interest

Dayforce's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAY#NYSE">DAY</a>) short percent of float has fallen 23.53% since its last report. The company recently reported that it has 7.60 million shares sold short, which is 7.28% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.79 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Dayforce Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739384110_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Dayforce has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Dayforce's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Dayforce's peer group average for short interest as a percentage of float is 4.82%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into Dayforce's Recent Short Interest

Rumors

GTLB

Watching GitLab; Hearing Investors Business Daily SwingTrader Buys Stock

Zelman &amp; Assoc analyst Jesse Lederman downgrades Hovnanian Enterprises (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HOV#NYSE">HOV</a>) from Neutral to Underperform.

Downgrades

Zelman & Assoc Downgrades Hovnanian Enterprises to Underperform

Morgan Stanley analyst Toni Kaplan maintains S&amp;P Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPGI#NYSE">SPGI</a>) with a Overweight and raises the price target from $595 to $600.

SPGI

Morgan Stanley Maintains Overweight on S&P Global, Raises Price Target to $600

Morgan Stanley analyst Keith Weiss maintains Shopify (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NYSE">SHOP</a>) with a Overweight and raises the price target from $126 to $144.

SHOP

Morgan Stanley Maintains Overweight on Shopify, Raises Price Target to $144

American International Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIG#NYSE">AIG</a>) shares are trading lower today. On Tuesday, the company reported that the fourth quarter adjusted EPS of&nbsp;$1.30&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43640648/aig-reports-outstanding-fourth-quarter-and-full-year-2024-results" rel="noreferrer noopener">exceeded the consensus of $1.23</a>.
Piper Sandler analyst Paul Newsome writes that results came in above consensus but slightly below his estimates due to weaker <a target="_blank" href="https://www.benzinga.com/quote/aig/analyst-ratings" rel="noreferrer noopener">underwriting results and higher expenses</a>.
However, catastrophe losses were in line with his expectations and better than consensus, adds the analyst.
Notably, he notes that AIG reported a 92.5% combined ratio, better than consensus (93.3%) but slightly above his estimate of 91.5%.
Despite some segment noise, the company avoided broader casualty issues, adds the analyst.
Overall, Newsome says investors will view the results as better than expected.
Keefe, Bruyette &amp; Woods analyst Meyer Shields notes that AIG&#8217;s fourth-quarter operating EPS beat their $1.09 estimate, led by stronger core and catastrophe loss ratios, reserve releases and investment income, partially offset by higher expenses and taxes.
The analyst expects shares to gain on the EPS beat and reaffirmed the 10%+ ROE target for 2025, though gains may be tempered by a higher-than-expected expense ratio.
Investors can gain exposure to the stock via Invesco KBW Property &amp; Casualty Insurance ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KBWP#NASDAQ">KBWP</a>) and iShares U.S. Insurance ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IAK#NYSE">IAK</a>).
Price Action: AIG shares are down 1.49% at $74.81 at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/25/01/42933396/californias-10-trillion-property-market-faces-unprecedented-threat-from-wildfires" target="_blank" rel="noreferrer noopener">California&#8217;s $10 Trillion Property Market Faces Unprecedented Threat From Wildfires</a></li>
</ul>
Photo: Shutterstock

Equities

Large Cap

iShares Dow Jones US Insurance Index Fund

KBWP

Analysts See AIG's Q4 As Positive, But Expense Ratio Limits Stock Gains

Morgan Stanley analyst Joshua Pokrzywinski maintains Rockwell Automation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROK#NYSE">ROK</a>) with a Overweight and raises the price target from $335 to $345.

Morgan Stanley Maintains Overweight on Rockwell Automation, Raises Price Target to $345

Federal Reserve

Fed's Goolsbee Says If We Got Multiple Months Like This (On CPI Inflation, Then The Job Is Clearly Not Done)

Morgan Stanley analyst Alex Poon maintains NetEase (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTES#NASDAQ">NTES</a>) with a Overweight and raises the price target from $108 to $117.

NTES

Morgan Stanley Maintains Overweight on NetEase, Raises Price Target to $117

Morgan Stanley analyst Sanjit Singh maintains Confluent (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CFLT#NASDAQ">CFLT</a>) with a Equal-Weight and raises the price target from $30 to $32.

CFLT

Morgan Stanley Maintains Equal-Weight on Confluent, Raises Price Target to $32

Citigroup analyst Steven Enders maintains BlackLine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BL#NASDAQ">BL</a>) with a Buy and lowers the price target from $73 to $70.

Citigroup Maintains Buy on BlackLine, Lowers Price Target to $70

MiNK Therapeutics, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INKT#NASDAQ">INKT</a>), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that it has been selected for an oral presentation at the upcoming&nbsp;American Association for Cancer Research (AACR) IO Annual Meeting that will take place on&nbsp;February 23-26 in Los Angeles, California. The oral presentation will highlight interim data from the company's ongoing Phase 2 study testing AgenT-797 in combination with Agenus' lead therapeutic combination, botensilimab and balstilimab (BOT/BAL), in patients with refractory (2L+) gastric cancer (<a href="https://www.globenewswire.com/Tracker?data=t6txOKgp_MgEu4o8gN9EhC8-aPrKqm-f_6rS_BW7tVdkK00bmuNqJAGLdL_BAlX-0LUj7fqSq4pXWnarGuDxoySa8PvggMqTPCB8tryykvE=">NCT06251973</a>).

Biotech

General

INKT

MiNK Therapeutics To Present Updated Data From Phase 2 Study Testing AgenT-797 In Gastric Cancer At AACR IO Annual Meeting

<a href="https://www.globenewswire.com/Tracker?data=RRfz9O6r4fGsE9THQr6YofXWnwlfA4EcG2CrfxhZPi7GP2cKD-RstD59AmdT2vJk0ReK04g74dKxsKQ-a91FYdOC546yGDERB2Iuc5TXa1k=">Red Cat Holdings, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCAT#NASDAQ">RCAT</a>) ("Red Cat"), a drone technology company integrating robotic hardware and software for military, government, and commercial operations, today announced it has entered into an agreement for up to $20 million and closed on the initial tranche of $16.5 Million in debt financing with The Lind Partners, a New York based institutional fund manager ("Lind"). Details of the agreement include:
<ul>
<li>Debt Financing convertible at $16.15 share price</li>
<li>Initial Tranche proceeds of $15 million</li>
<li>1 million warrants exercisable at $15.00 per share non cashless &nbsp;</li>
</ul>
Additionally, Red Cat has applied for $58 million in debt financing from the <a href="https://www.globenewswire.com/Tracker?data=31XzAh54dnto-MDxoRJEw-pG3ON3Z0v5FYpnv-NLc6smewtIUFSZEP0QdbDBtqJKE4vxZ-sqNfTD1jRhVS3jJExWx_7a49m7LDQowXZGAb1Cg_DH-fS4rUKqfBJKSk_Q3QwCsJmlziFWEa58e3COAg==">Department of Defense Office of Strategic Capital</a> (OSC). OSC implements strategies and partnerships to accelerate and scale private investment in critical supply chain technologies needed for national security. They have identified 14 critical technology areas vital to maintaining the United States' national security. These have been grouped into three categories as found in the 2023 National Defense Science and Technology Strategy.
<ul>
<li>Seed Areas of Emerging Opportunity</li>
<li>Effective Adoption Areas</li>
<li>Defense-Specific Areas &nbsp;</li>
</ul>
The investment is expected to provide Red Cat with the working capital needed to scale up production and the ongoing development of its Arachnid Family of Systems, which includes Black Widow&#x2122;, Edge 130, and a new line of FANG&#x2122; First-Person View (FPV) drones. The goal of the Family of Systems is to meet the needs of the U.S. Department of Defense and NATO Allies for drone systems that are low-cost, portable, field repairable, and recoverable.

Financing

RCAT

Red Cat Announces It Has Entered Into An Agreement For Up To $20M And Closed On The Initial Tranche Of $16.5M In Debt Financing With The Lind Partners, A New York Based Institutional Fund Manager

In the last three months, 7 analysts have published ratings on Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>), offering a diverse range of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $284.57, a high estimate of $301.00, and a low estimate of $255.00. Observing a 2.41% increase, the current average has risen from the previous average price target of $277.86. 
<img src="https://www.benzinga.com/files/images/story/2025/1739383265_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Humana. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$283.00</td>
<td>$283.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$290.00</td>
<td>$290.00</td>
</tr>
<tr>
<td>Erin Wright</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$285.00</td>
<td>$301.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$255.00</td>
<td>$253.00</td>
</tr>
<tr>
<td>Jessica Tassan</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$288.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$290.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Erin Wright</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$301.00</td>
<td>$288.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Humana. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Humana compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Humana's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Humana's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/HUM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Humana analyst ratings.</a>
<h2>About Humana</h2>
Humana is one of the largest private health insurers in the us with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
<h3>Humana: Financial Performance Dissected</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Positive Revenue Trend: Examining Humana's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 11.26% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Humana's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.63% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Humana's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.8% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Humana's ROA stands out, surpassing industry averages. With an impressive ROA of 0.96%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Humana's debt-to-equity ratio stands notably higher than the industry average, reaching 0.74. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Analyst Ratings: What Are They?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into Humana Stock: Analyst Perspectives (7 Ratings)

Citi says 'buy' these stocks in '25; SA Quant Ratings says maybe not

Night Watch Investment Management Q4 2024 Update

There's a lot to be optimistic about in the Technology sector as 2 analysts just weighed in on Remitly Global (RELY – Research Report) and TTM Tech...

Analysts Offer Insights on Technology Companies: Remitly Global (RELY) and TTM Technologies (TTMI)

Citi analyst Andrew Schmidt suggests investors open a pair trade of being overweight Remitly Global (RELY) and underweight Western Union (WU). Ther...

Citi suggests pair trade of overweight Remitly, underweight Western Union

Remitly Global: I Expect Consistent Profitability Going Forward

Wells Fargo analyst Andrew Bauch maintained a Hold rating on Remitly Global (RELY – Research Report) today and set a price target of $21.00. The co...

Wells Fargo Sticks to Its Hold Rating for Remitly Global (RELY)

Remitly Global ( ($RELY) ) just unveiled an announcement. On January 21, 2025, Gail Miller, the Chief Accounting Officer of Remitly Global, Inc., a...

Remitly Global Appoints New Chief Accounting Officer

There's a lot to be optimistic about in the Technology sector as 3 analysts just weighed in on Varonis Systems (VRNS – Research Report), Airgain (A...

Analysts Are Bullish on These Technology Stocks: Varonis Systems (VRNS), Airgain (AIRG)

Barclays raised the firm's price target on Remitly Global (RELY) to $28 from $23 and keeps an Overweight rating on the shares. The firm updated the...

Remitly Global price target raised to $28 from $23 at Barclays

Pernas Research Q4 2024 Investment Letter

AIRG

ALLY

AMRK

ATRO

ATROB

BPOP

CPAY

CTVA

CYBR

DOCMF

DRMMF

DRMTY

DSGR

DUOL

EVRG

EXAS

FNNTF

HOEGF

IMVT

MLXSF

PEGA

PIAIF

PNGAY

PODD

PTEN

RARE

RELY

RRGB

SLGN

TSSI

TTMI

UPWK

VRNS

WTTR

XFABF

XMTR

Press Releases

Remitly to Report Second Quarter Financial Results on Wednesday, July 31, 2024

Earnings

Remitly Reports Second Quarter 2024 Results

Management

Remitly Announces CFO Transition Plan

Remitly to Present at the 2024 Goldman Sachs Communacopia + Technology Conference

Mendaera Closes $73M Series B Financing to Scale Robotics and AI Across Mainstream Medical Procedures

Remitly to Report Third Quarter Financial Results on Wednesday, October 30, 2024

Remitly Reports Third Quarter 2024 Results and Raises Full Year 2024 Outlook

Remitly to Present at the 2024 Wells Fargo TMT Summit

Markets

KBW Announces Index Rebalancing for Fourth-Quarter 2024

Remitly to Report Fourth Quarter and Full Year 2024 Financial Results on February 19, 2025

Comments

Remitly Global

Remitly Global (RELY) オプション

Remitly Global (NASDAQ:RELY) 株価情報, オプションチェーン

ニュース

パートナーシップ

ベンジンガ・グローバル